CC
ADVM

Casdin Capital’s Adverum Biotechnologies ADVM Stock Holding History

Casdin Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-221,162
Closed -$21.8M – 55
2021
Q1 		$21.8M Sell
221,162
-143,838
-39% -$17.3M 0.65% 32
2020
Q4 		$39.6M Buy
365,000
+90,000
+33% +$11.1M 1.17% 23
2020
Q3 		$28.3M Buy
275,000
+88,500
+47% +$13.3M 1.27% 22
2020
Q2 		$38.9M Buy
186,500
+74,000
+66% +$13.1M 2.3% 15
2020
Q1 		$11M Buy
+112,500
New +$13.1M 1.17% 26
2018
Q2 		– Sell
-30,000
Closed -$1.74M – 36
2018
Q1 		$1.74M Buy
+30,000
New +$1.87M 0.31% 30
2017
Q2 		– Sell
-42,000
Closed -$1.13M – 36
2017
Q1 		$1.13M Buy
+42,000
New +$1.19M 0.67% 28

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Casdin Capital's ADVM Position: Q2 2021 in Review

Casdin Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 221,162 shares — an estimated $21.8M sold.

Casdin Capital first reported a position in ADVM in Q1 2017 and held it in 7 quarters. The position peaked at $39.6M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Casdin Capital reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Casdin Capital sold 221,162 Adverum Biotechnologies shares in Q2 2021, an estimated $21.8M.
  • Casdin Capital first reported a position in Adverum Biotechnologies in Q1 2017 and held it in 7 quarters.
  • Casdin Capital's Adverum Biotechnologies position peaked at $39.6M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.